Cargando…
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
BACKGROUND: TP53 mutation is more prevalent in therapy-related myeloid neoplasms (t-MN) than their de novo counterparts; however, the pattern of mutations involving TP53 gene in t-MN versus de novo diseases is largely unknown. METHODS: We collected 108 consecutive patients with therapy-related myelo...
Autores principales: | Ok, Chi Young, Patel, Keyur P, Garcia-Manero, Guillermo, Routbort, Mark J, Peng, Jie, Tang, Guilin, Goswami, Maitrayee, Young, Ken H, Singh, Rajesh, Medeiros, L Jeffrey, Kantarjian, Hagop M, Luthra, Rajyalakshmi, Wang, Sa A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431603/ https://www.ncbi.nlm.nih.gov/pubmed/25952993 http://dx.doi.org/10.1186/s13045-015-0139-z |
Ejemplares similares
-
RAS and TP53 can predict survival in adults with T‐cell lymphoblastic leukemia treated with hyper‐CVAD
por: Sakhdari, Ali, et al.
Publicado: (2019) -
Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis
por: Kanagal-Shamanna, Rashmi, et al.
Publicado: (2021) -
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
por: Takahashi, Koichi, et al.
Publicado: (2016) -
Clinical features of De Novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
por: Loghavi, Sanam, et al.
Publicado: (2014) -
TP53-Mutated Myelodysplastic Syndrome and Acute Myeloid Leukemia: Biology, Current Therapy, and Future Directions
por: Daver, Naval G., et al.
Publicado: (2022)